biotech · Chronic Inducible Urticaria · Chronic Spontaneous Urticaria · JSPR
Jasper Therapeutics
Jasper Therapeutics is a biotech organization headquartered in Redwood City, USA. It trades on NYSE under ticker JSPR. Primary therapeutic focus areas include Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, a
Redwood City, CA, US HQ
44 Employees
Public company Type
JSPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Redwood City, CA, US
- Employees
- 44
- Programs
- 13
- Drugs
- 13
- Patents
- 1
JSP191
Phase 1 · small molecule · Lower-risk Myelodysplastic Syndrome
JSP191 for Lower-risk Myelodysplastic Syndrome is a Phase 1 program (small_molecule) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code JSP-CP-008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jasper Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Lower-risk Myelodysplastic Syndrome
- Status
- terminated
- Trials
- 1